VISIOMED GROUP (ALVMG.PA)
FR0013481835 - Common Stock
ALVMG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 54 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALVMG have multiple concerns. ALVMG is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ALVMG has reported negative net income.
In the past year ALVMG has reported a negative cash flow from operations.
ALVMG had negative earnings in each of the past 5 years.
ALVMG had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -10.01%, ALVMG is doing worse than 64.15% of the companies in the same industry.
ALVMG has a worse Return On Equity (-15.50%) than 62.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.01% | ||
| ROE | -15.5% | ||
| ROIC | N/A |
ROA(3y)-37.3%
ROA(5y)-76.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 91.46%, ALVMG belongs to the best of the industry, outperforming 92.45% of the companies in the same industry.
ALVMG's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ALVMG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y29.85%
GM growth 5Y8.03%
2. Health
2.1 Basic Checks
ALVMG does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALVMG has more shares outstanding than it did 1 year ago.
ALVMG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALVMG is higher compared to a year ago.
2.2 Solvency
ALVMG has an Altman-Z score of 2.45. This is not the best score and indicates that ALVMG is in the grey zone with still only limited risk for bankruptcy at the moment.
ALVMG's Altman-Z score of 2.45 is in line compared to the rest of the industry. ALVMG outperforms 58.49% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that ALVMG is not too dependend on debt financing.
ALVMG has a Debt to Equity ratio (0.36) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.45 |
ROIC/WACCN/A
WACC7.14%
2.3 Liquidity
ALVMG has a Current Ratio of 1.70. This is a normal value and indicates that ALVMG is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.70, ALVMG is in line with its industry, outperforming 49.06% of the companies in the same industry.
ALVMG has a Quick Ratio of 1.70. This is a normal value and indicates that ALVMG is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ALVMG (1.70) is better than 66.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.7 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 32.19% over the past year.
ALVMG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -22.93%.
The Revenue has been growing slightly by 6.67% on average over the past years.
EPS 1Y (TTM)32.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q72.51%
Revenue 1Y (TTM)-22.93%
Revenue growth 3Y12.16%
Revenue growth 5Y6.67%
Revenue growth Q2Q-27.34%
3.2 Future
Based on estimates for the next years, ALVMG will show a very strong growth in Earnings Per Share. The EPS will grow by 54.99% on average per year.
The Revenue is expected to grow by 24.40% on average over the next years. This is a very strong growth
EPS Next Y100%
EPS Next 2Y60.45%
EPS Next 3Y54.99%
EPS Next 5YN/A
Revenue Next Year-7.3%
Revenue Next 2Y14.23%
Revenue Next 3Y24.4%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALVMG. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 18.41, the valuation of ALVMG can be described as rather expensive.
71.70% of the companies in the same industry are more expensive than ALVMG, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of ALVMG to the average of the S&P500 Index (21.26), we can say ALVMG is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.41 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ALVMG's earnings are expected to grow with 54.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.45%
EPS Next 3Y54.99%
5. Dividend
5.1 Amount
No dividends for ALVMG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VISIOMED GROUP
EPA:ALVMG (4/19/2024, 7:00:00 PM)
0.1896
0 (-1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap55.79M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 18.41 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.01% | ||
| ROE | -15.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.46% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.7 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)32.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y100%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-22.93%
Revenue growth 3Y12.16%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y